NCT05797506View on ClinicalTrials.gov

Safety, Feasibility and Efficacy of Sulforaphane (Avmacol Extra Strength) in Chronic Kidney Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 3, 2023

Primary Completion Date

April 25, 2025

Study Completion Date

December 31, 2025

Conditions
Chronic Kidney Disease Stage 3Chronic Kidney Disease Stage 4
Interventions
DRUG

Sulforaphane (Avmacol Extra Strength)

4 Tablets of Sulforaphane (Avmacol Extra Strength) per day in patients with Chronic Kidney Disease, stages 3-4.

DIETARY_SUPPLEMENT

Placebo

These tablets will be matched placebos and will be provided by Avmacol.

Trial Locations (1)

14642

University of Rochester Medical Center, Rochester

Sponsors
All Listed Sponsors
collaborator

University of Virginia

OTHER

collaborator

Nutramax Laboratories, Inc.

INDUSTRY

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Rochester

OTHER

NCT05797506 - Safety, Feasibility and Efficacy of Sulforaphane (Avmacol Extra Strength) in Chronic Kidney Disease | Biotech Hunter | Biotech Hunter